192 related articles for article (PubMed ID: 24516522)
1. Utility of 18F-FDG PET with a semi-quantitative index in the detection of sarcomatous transformation in patients with neurofibromatosis type 1.
Combemale P; Valeyrie-Allanore L; Giammarile F; Pinson S; Guillot B; Goulart DM; Wolkenstein P; Blay JY; Mognetti T
PLoS One; 2014; 9(2):e85954. PubMed ID: 24516522
[TBL] [Abstract][Full Text] [Related]
2. [Utility of 18 FDG positon emission tomography in detection of sarcomatous transformation in neurofibromatosis type 1].
Bensaid B; Giammarile F; Mognetti T; Galoisy-Guibal L; Pinson S; Drouet A; Combemale P
Ann Dermatol Venereol; 2007 Oct; 134(10 Pt 1):735-41. PubMed ID: 17978710
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
Chirindel A; Chaudhry M; Blakeley JO; Wahl R
J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
[TBL] [Abstract][Full Text] [Related]
4. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
[TBL] [Abstract][Full Text] [Related]
5. Metabolic Tumour Burden Measured by 18F-FDG PET/CT Predicts Malignant Transformation in Patients with Neurofibromatosis Type-1.
Van Der Gucht A; Zehou O; Djelbani-Ahmed S; Valeyrie-Allanore L; Ortonne N; Brugières P; Wolkenstein P; Luciani A; Rahmouni A; Sbidian E; Itti E
PLoS One; 2016; 11(3):e0151809. PubMed ID: 26987124
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.
Reinert CP; Schuhmann MU; Bender B; Gugel I; la Fougère C; Schäfer J; Gatidis S
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):776-787. PubMed ID: 30535768
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.
Salamon J; Veldhoen S; Apostolova I; Bannas P; Yamamura J; Herrmann J; Friedrich RE; Adam G; Mautner VF; Derlin T
Eur Radiol; 2014 Feb; 24(2):405-12. PubMed ID: 24097302
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1.
Salamon J; Derlin T; Bannas P; Busch JD; Herrmann J; Bockhorn M; Hagel C; Friedrich RE; Adam G; Mautner VF
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):685-92. PubMed ID: 23232507
[TBL] [Abstract][Full Text] [Related]
9. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.
Warbey VS; Ferner RE; Dunn JT; Calonje E; O'Doherty MJ
Eur J Nucl Med Mol Imaging; 2009 May; 36(5):751-7. PubMed ID: 19142634
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of
Geitenbeek RTJ; Martin E; Graven LH; Broen MPG; Anten MHME; van der Pol JAJ; Verhoef C; Taal W
J Neurooncol; 2022 Feb; 156(3):559-567. PubMed ID: 35025020
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the most commonly used (semi-)quantitative parameters of 18F-FDG PET/CT to detect malignant transformation of neurofibromas in neurofibromatosis type 1.
Brinkman M; Jentjens S; Boone K; Anten M; Stumpel CTRM; Nelemans PJ; van Kroonenburgh MJPG
Nucl Med Commun; 2018 Nov; 39(11):961-968. PubMed ID: 30106798
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
Derlin T; Tornquist K; Münster S; Apostolova I; Hagel C; Friedrich RE; Wedegärtner U; Mautner VF
Clin Nucl Med; 2013 Jan; 38(1):e19-25. PubMed ID: 23242059
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [
Azizi AA; Slavc I; Theisen BE; Rausch I; Weber M; Happak W; Aszmann O; Hojreh A; Peyrl A; Amann G; Benkoe TM; Wadsak W; Kasprian G; Staudenherz A; Hacker M; Traub-Weidinger T
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28771999
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.
Brahmi M; Thiesse P; Ranchere D; Mognetti T; Pinson S; Renard C; Decouvelaere AV; Blay JY; Combemale P
PLoS One; 2015; 10(10):e0138386. PubMed ID: 26445379
[TBL] [Abstract][Full Text] [Related]
15. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.
Tsai LL; Drubach L; Fahey F; Irons M; Voss S; Ullrich NJ
J Neurooncol; 2012 Jul; 108(3):469-75. PubMed ID: 22407214
[TBL] [Abstract][Full Text] [Related]
16. Value of PET in the assessment of patients with neurofibromatosis type 1.
Bredella MA; Torriani M; Hornicek F; Ouellette HA; Plamer WE; Williams Z; Fischman AJ; Plotkin SR
AJR Am J Roentgenol; 2007 Oct; 189(4):928-35. PubMed ID: 17885067
[TBL] [Abstract][Full Text] [Related]
17. Limitations and benefits of FDG-PET/CT in NF1 patients with nerve sheath tumors: A cross-sectional/longitudinal study.
Nishida Y; Ikuta K; Ito S; Urakawa H; Sakai T; Koike H; Ito K; Imagama S
Cancer Sci; 2021 Mar; 112(3):1114-1122. PubMed ID: 33415792
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of
Cook GJR; Lovat E; Siddique M; Goh V; Ferner R; Warbey VS
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1845-1852. PubMed ID: 28589254
[TBL] [Abstract][Full Text] [Related]
19. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
Karabatsou K; Kiehl TR; Wilson DM; Hendler A; Guha A
Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
[TBL] [Abstract][Full Text] [Related]
20. Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
Ahlawat S; Blakeley JO; Rodriguez FJ; Fayad LM
Neurology; 2019 Sep; 93(11):e1076-e1084. PubMed ID: 31395668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
